Swiss stocks - Factors to watch on January 14

BERLIN/ZURICH, Jan 14 (Reuters) - The Swiss blue-chip SMI was seen opening 0.2% higher at 10,639 points on Tuesday, according to premarket indications from bank Julius Baer.

Here are some of the main factors that may affect Swiss stocks:


The Swiss drugmaker and Britain’s National Health Service (NHS) on Monday announced a pact that will clear the way for accelerated review by the country’s health watchdog NICE for heart drug inclisiran, which could make it broadly available as soon as 2021.

For more, click on


The Swiss chocolate maker said it wants to keep growing 5-7% per year in the mid term after strong growth in Europe and the opening of new Lindt stores boosted organic sales by 6.1% in 2019. Shares were indicated to open 1.6% higher.

For more, click on


Shares in Switzerland-based banking software maker Temenos fell as much as 4% on Monday, with two traders attributing the move to London hedge fund manager ShadowFall saying it had shorted the company’s stock.

For more, click on


* Aryzta AG said Tyson Yu was appointed as CEO of ARYZTA North America and as a member of the Group Executive Committee, while Dave Johnson assumes the role of Non-Executive Chairman of ARYZTA North America and John Heffernan was appointed as President and Chief Commercial Officer North America.

* Ascom said it won a contract for the Turku University Hospital and its campus expansion T3 worth around 1.5 million Swiss francs.

* BKW sait it raised its expectations for 2019 earnings, expecting both EBIT and net income to exceed previous year’s levels.

* Glarner Kantonalbank said it appointed Michaela Ernst to the executive board.

* Partners Group said it acquired a majority equity stake in a portfolio of 30 commercial properties in Germany, France and the Netherlands for a total transaction value of over 550 million euros ($612.81 million).

* Roche said it had entered into a 15-year, non-exclusive partnership with Illumina to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology.

* Bossard Holding reported fiscal year group sales of CHF 876.2 million compared with CHF 871.1 million the previous year.

* Rapid Nutrition Plc reported first-half revenue of $1.78 million and said the second half of the year had begun strongly through retail channels.

* Flughafen Zuerich said the number of passengers in December was up by 1.2%.


* LOGITECH INTERNATIONAL: JP Morgan cuts to neutral from overweight

* INTERROLL HOLDING: Credit Suisse initiates with neutral rating and CHF 2,300 target price

* Inficon: Credit Suisse initiaties with Underperform rating and 636 Swiss franc target price


No major economic data scheduled.

$1 = 0.8975 euros Reporting by Zurich newsroom and Berlin Speed Desk